Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
Crossref DOI link: https://doi.org/10.1038/bcj.2015.93
Published Online: 2015-11-13
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ysebaert, L
Laprévotte, E
Klein, C
Quillet-Mary, A
Text and Data Mining valid from 2015-11-13
Version of Record valid from 2015-11-13
Article History
First Online: 13 November 2015
Competing interests
: CK is an employee of Hoffmann La Roche. The remaining authors declare no conflict of interest.